Client News

Roquefort Therapeutics plc: Notice of Admission
Home / Client News / Roquefort Therapeutics plc: Notice of Admission

Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, confirms that application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 57,249,998 new Ordinary Shares, comprising 50,000,000 Consideration Shares and 7,249,998 Placing Shares of £0.01 each, to the Official List of the UKLA by way of a standard listing under Chapter 14 of the UKLA’s Listing Rules and to trading on the London Stock Exchange’s main market for listed securities (“Admission”). Admission will take place at 8:00a.m. tomorrow.

Completion of the Acquisition and the Placing will become effective on Admission.

Capitalised terms used in this announcement (unless otherwise defined) carry the same meanings as those ascribed to them in the Company’s Prospectus dated 13 September 2022, unless the context requires otherwise.

Full Details:


If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.


Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

Share This